Please use this identifier to cite or link to this item:

Full metadata record
DC FieldValueLanguage
dc.contributor.authorFerreira, Natália N.por
dc.contributor.authorFerreira, Leonardo M.B.por
dc.contributor.authorMiranda-Gonçalves, Verapor
dc.contributor.authorReis, R. M.por
dc.contributor.authorSeraphim, Thiago V.por
dc.contributor.authorBorges, Júlio Césarpor
dc.contributor.authorBaltazar, Fátimapor
dc.contributor.authorGremião, Maria Palmira D.por
dc.identifier.citationFerreira, N. N., Ferreira, L. M., Miranda-Gonçalves, V., Reis, R. M., Seraphim, T. V., Borges, J. C., ... & Gremião, M. P. D. (2017). Alginate hydrogel improves anti-angiogenic bevacizumab activity in cancer therapy. European Journal of Pharmaceutics and Biopharmaceutics, 119, 271-282por
dc.descriptionAlginate hydrogel improves anti-angiogenic bevacizumab activity in cancer therapypor
dc.description.abstractAnti-vascular endothelial growth factor (anti-VEGF) therapy applied to solid tumors is a promising strategy, yet, the challenge to deliver these agents at high drug concentrations together with the maintenance of therapeutic doses locally, at the tumor site, minimizes its benefits. To overcome these obstacles, we propose the development of a bevacizumab-loaded alginate hydrogel by electrostatic interactions to design a delivery system for controlled and anti-angiogenic therapy under tumor microenvironrnental conditions. The tridimensional hydrogel structure produced provides drug stability and a system able to be introduced as a flowable solution, stablishing a depot after local administration. Biological performance by the chick embryo chorioallantoic membrane (CAM) assay indicated a pH-independent improved anti-angiogenic activity (similar to 50%) compared to commercial available anti-VEGF drug. Moreover, there was a considerable regression in tumor size when treated with this system. Immunohistochemistry highlighted a reduced number and disorganization of microscopic blood vessels resulting from applied therapy. These results suggest that the developed hydrogel is a promising approach to create an innovative delivery system.that offers the possibility to treat different solid tumors by intratumoral administration.por
dc.description.sponsorshipBrazilian Fundação de Amparo e Pesquisa do Estado de São Paulo (FAPESP), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq). Additionally, this article has been developed under the scope of the project NORTE-01-0145-FEDER-000013, supported by the Northern Portugal Regional Operational Programme (NORTE 2020), under the Portugal 2020 Partnership Agreement, through the European Regional Development Fund (FEDER) Project PTDC/SAU-TOX/114549/2009 – FCOMP-01-0124-FEDER-016057, through the Competitiveness Factors Operational Programme (COMPETE), and by National funds, through the Foundation for Science and Technology (FCT), under the scope of the project POCI-01-0145-FEDER-007038por
dc.subjectProtein delivery systempor
dc.subjectCalcium alginate hydrogelpor
dc.subjectTumor microenvironmentpor
dc.subjectSupramolecular interactionspor
dc.titleAlginate hydrogel improves anti-angiogenic bevacizumab activity in cancer therapypor
dc.subject.fosCiências Naturais::Ciências Físicaspor
dc.subject.wosScience & Technologypor
sdum.journalEuropean Journal of Pharmaceutics and Biopharmaceuticspor
Appears in Collections:ICVS - Artigos em Revistas Internacionais com Referee

Files in This Item:
File Description SizeFormat 
2017 ferreirann.pdf2,48 MBAdobe PDFView/Open

Partilhe no FacebookPartilhe no TwitterPartilhe no DeliciousPartilhe no LinkedInPartilhe no DiggAdicionar ao Google BookmarksPartilhe no MySpacePartilhe no Orkut
Exporte no formato BibTex mendeley Exporte no formato Endnote Adicione ao seu ORCID